Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002;16(1):30-6.
doi: 10.1002/jcla.2072.

Quantification of antigen-reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells

Affiliations

Quantification of antigen-reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells

M Schmitz et al. J Clin Lab Anal. 2002.

Abstract

The enzyme-linked immunospot (ELISPOT) assay has become a widely employed method for quantification of antigen-reactive T lymphocytes. In recent years, various types of antigen-presenting cells (APCs) have been tested as stimulator cells in ELISPOT protocols to achieve a highly sensitive and rapid assay which is not impaired by a marked nonspecific cytokine release. However, the currently available APCs still have disadvantages, such as significant background reactivities, limited sensitivity, and time-consuming preparation procedures. Recently, we succeeded in defining a novel subpopulation of circulating dendritic cells (DCs) that can easily be prepared from human blood. These M-DC8+ DCs proved to be very effective in the induction of antigen-specific T cell responses. In the present study we provide evidence that M-DC8+ DCs are particularly well suited as APCs for the detection of antigen-specific CD8+ T cells after challenge with viral or tumor peptides in ELISPOT assays. In addition, protein-loaded M-DC8+ DCs proved to be quite efficient in the presentation of MHC class II-bound peptides, thus allowing the determination of frequencies of antigen-reactive CD4+ T cells. The use of M-DC8+ DCs as stimulator cells can improve the ELISPOT assay by combining high sensitivity, rapidity, and low background reactivity.

PubMed Disclaimer

Similar articles

References

    1. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321–327. - PMC - PubMed
    1. Marchand M, Van Baren N, Weynants P, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1. Int J Cancer 80:219–230. - PubMed
    1. Townsend A, Bodmer H. 1989. Antigen recognition by class‐I restricted T lymphocytes. Annu Rev Immunol 7:601–624. - PubMed
    1. Rosenberg SA, Yannelli JR, Yang JC, et al. 1994. Treatment of patients with metastatic melanoma with autologous tumor‐infiltrating lymphocytes and interleukin‐2. J Natl Cancer Inst 86:1159–1166. - PubMed
    1. Pardoll DM, Topalian SL. 1998. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10:588–594. - PubMed

Publication types

MeSH terms